Rigor Reviewed

Rigor-Reviewed Manuscript

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.

Name: Αlpha¹ Rigor Record — BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Item: BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Rating: 96
Author: Αlpha¹

Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M, BCG REVAX Study Team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.25★ (Weak), 0 critical, 4 high issues for “BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2b randomized controlled trial. The main strengths are the rigorous design, clear statistical analysis, and transparent reporting. The primary weakness is the lack of a clear data availability statement, which is a notable omission for a clinical trial.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable for a human clinical trial (e.g., species/strain, housing conditions, cell line authentication). The statistics verification component checked only 2 tests (both consistent), so the statistical analysis is not fully verified. The citation component found no retracted or unresolved references.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites the prior phase 2 trial (NCT02075203) that showed BCG revaccination prevented sustained Mtb infection (VE 45%, 95% CI 6% to 68%) as a secondary endpoint. The rationale for the current trial is clearly stated: to confirm that finding in a larger, more diverse population and to identify correlates of protection. The paper acknowledges limitations of the prior trial, including that VE for prevention of sustained infection may not predict VE for prevention of disease, and that the prior trial was not powered for the primary endpoint of sustained infection.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise based on prior trial results and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 2]

“A prior phase 2 trial assessed the efficacy of the investigational H4:IC31 vaccine and Bacille Calmette-Guérin (BCG) vaccine versus placebo for protection against Mtb infection in healthy 12–17-year-old IGRA-negative, HIV-negative participants in South Africa.”

direct quote[Introduction, paragraph 3]

“we set out to: a) confirm that BCG revaccination confers prevention of sustained Mtb infection in a larger population with expanded age range and geographical area;”